Company Description

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.

Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.

The company was founded in 2009 and is headquartered in Mountain View, California.

RenovoRx, Inc.

Country	United States
Founded	2012
IPO Date	Aug 26, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	17
CEO	Shaun Bagai

Contact Details

Address: 2570 West El Camino Real, Suite 320 Mountain View, California 94040 United States
Phone	650 284 4433
Website	renovorx.com

Stock Details

Ticker Symbol	RNXT
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$9.00
CIK Code	1574094
CUSIP Number	75989R107
ISIN Number	US75989R1077
Employer ID	27-1448452
SIC Code	2834

Key Executives

Name	Position
Shaun R. Bagai	Chief Executive Officer, Secretary and Director
Dr. Ramtin Agah M.D.	Founder, Executive Chairman and Chief Medical Officer
Ronald B. Kocak CPA, CGMA	Vice President of Finance and Controller
Mark Voll	Chief Financial Officer and Principal Accounting Officer
Tom Kelly	Vice President of Quality and Operations
Phil Stocton	Vice President of Sales and Market Development
Leesa Gentry	Chief Clinical Officer

Latest SEC Filings

Date	Type	Title
Aug 20, 2026	8-K	Current Report
Aug 13, 2026	10-Q	Quarterly Report
Aug 13, 2026	8-K/A	[Amend] Current report
Aug 12, 2026	8-K	Current Report
Aug 4, 2026	8-K	Current Report
Jul 2, 2026	8-K	Current Report
Jun 30, 2026	S-8	Securities to be offered to employees in employee benefit plans
Jun 30, 2026	8-K	Current Report
May 15, 2026	10-K/A	[Amend] Annual report
May 14, 2026	10-Q	Quarterly Report

View All SEC Filings